ENTITY
BeiGene

BeiGene (6160 HK)

328
Analysis
Health CareChina
BeiGene, Ltd. operates as a commercial stage biopharmaceutical company. The Company focuses on discovery, development, and commercialization of molecularly targeted and immuno-oncology drugs for the treatment of cancer. BeiGene serves patients worldwide.
more
11 Mar 2020 16:48

InnoCare Pharma IPO: Valuation Easy to Swallow

InnoCare Pharma Ltd (9969 HK) is a pre-revenue biotech company with a focus on research and development, manufacturing and commercialisation of...

Logo
472 Views
Share
05 Mar 2020 10:35

A Bottom Has Been Established; Possible Retest?

In today’s report we outline  our belief that the combination of extreme oversold conditions and several key sectors/industries holding above major...

Logo
369 Views
Share
11 Feb 2020 00:32

InnoCare Pharma IPO Initiation: Promising Prognosis

InnoCare Pharma Ltd (1576300D CH) is a pre-revenue biotech company with a focus on research and development, manufacturing and commercialisation of...

Logo
390 Views
Share
03 Feb 2020 13:37

Akesobio (康方生物) Pre-IPO: Late in the PD-1 Game but Products Are Promising

Akesobio is a clinical-stage biopharmaceutical company with a focus on developing biologics drugs for oncology and autoimmune. The company plans to...

Logo
614 Views
Share
bullishS&P 500 INDEX
20 Dec 2019 06:10

MSCI ACWI, STOXX 600 Breaking Out, Adding Fuel for Further U.S. Equity Market Rally

In today’s report we reiterate our bullish U.S. investment thesis, recap significant technical levels across indexes, and highlight attractive...

Logo
648 Views
Share
x